<DOC>
	<DOC>NCT00363142</DOC>
	<brief_summary>This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or once-daily.</brief_summary>
	<brief_title>A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects</brief_title>
	<detailed_description>A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week study to evaluate the safety, efficacy and tolerability of switching from a 200mg ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily, 100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Inclusion criteria: Subjects with HIV1 infection. Are willing and able to understand and provide written consent prior to participation in this study. Exclusion criteria: Are pregnant or breastfeeding. Have an active AIDS condition, pancreatitis, poor kidney function, or clinically relevant hepatitis. Have certain medical conditions that may make participation unsafe. Take medication that may interact with the study medication. Have a history of allergy to any of the study drugs or any excipients therein. Other inclusion/exclusion criteria to be evaluated by the physician.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV-1 LEXIVA Ritonavir Once-daily</keyword>
</DOC>